Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Effect of Sedative-Hypnotic Medicines on Mortality in Peritoneal Dialysis Patients with Sleep Disorders: A Retrospective Cohort Study

Zhou Y.a,b,c · Yin P.a,b · Li B.a,b,d · Li J.a,b · Huang N.a,b · Wu H.a,b · Ullah H.a,b · Yang X.a,b · Yu X.a,b

Author affiliations

aDepartment of Nephrology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
bKey Laboratory of Nephrology, Ministry of Health and Guangdong Province, Guangzhou, China
cDepartment of Nephrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
dClinical Research Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

Related Articles for ""

Blood Purif 2018;45:95–101

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: April 24, 2017
Accepted: November 02, 2017
Published online: December 12, 2017
Issue release date: Published online first (Issue-in-Progress)

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 4

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU

Abstract

Background: Sedative-hypnotic medication is widely used among continuous ambulatory peritoneal dialysis (CAPD) patients with sleep disorders; however, its effect on mortality has rarely been investigated. Methods: Logistic regression was employed to identify factors associated with sedative-hypnotic medication, whose effect on mortality was evaluated by Cox proportional hazards models. Results: A total of 146 CAPD patients with sleep disorders were recruited, of which 46 patients (31.5%) used either benzodiazepines or zolpidem. Sedative-hypnotic medication was more frequently used by older patients and those with longer duration of CAPD therapy and there was no significant association between sedative-hypnotic medicines and all-cause mortality after adjusting for age, gender, diabetes, cardiovascular disease, and duration of CAPD. Conclusion: Sedative-hypnotic medication was more often used by older patients and patients with a longer duration of CAPD. There was no association between these agents and all-cause mortality in CAPD patients with sleep disorders.

© 2017 S. Karger AG, Basel


References

  1. Murtagh FE, Addington-Hall J, Higginson IJ: The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis 2007; 14: 82–99.
  2. Hui DS, Wong TY, Ko FW, Li TS, Choy DK, Wong KK, Szeto CC, Lui SF, Li PK: Prevalence of sleep disturbances in chinese patients with end-stage renal failure on continuous ambulatory peritoneal dialysis. AMJ Kidney Dis 2000; 36: 783–788.
  3. De Vecchi A, Finazzi S, Padalino R, Santagostino T, Bottaro E, Roma E, Bossi R: Sleep disorders in peritoneal and haemodialysis patients as assessed by a self-administered questionnaire. Int J Artif Organs 2000; 23: 237–242.
    External Resources
  4. Yngman-Uhlin P, Johansson A, Fernstrom A, Borjeson S, Edell-Gustafsson U: Fragmented sleep: an unrevealed problem in peritoneal dialysis patients. Scand J Urol Nephrol 2011; 45: 206–215.
  5. Stepanski E, Faber M, Zorick F, Basner R, Roth T: Sleep disorders in patients on continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995; 6: 192–197.
    External Resources
  6. Mucsi I, Molnar MZ, Rethelyi J, Vamos E, Csepanyi G, Tompa G, Barotfi S, Marton A, Novak M: Sleep disorders and illness intrusiveness in patients on chronic dialysis. Nephrol Dial Transplant 2004; 19: 1815–1822.
  7. Winkelmayer WC, Mehta J, Wang PS: Benzodiazepine use and mortality of incident dialysis patients in the United States. Kidney Int 2007; 72: 1388–1393.
  8. Ashton H: Guidelines for the rational use of benzodiazepines. When and what to use. Drugs 1994; 48: 25–40.
  9. Neutel CI: The epidemiology of long-term benzodiazepine use. Int Rev Psychiatry 2005; 7: 189–197.
  10. Fukuhara S, Green J, Albert J, Mihara H, Pisoni R, Yamazaki S, Akiba T, Akizawa T, Asano Y, Saito A, Port F, Held P, Kurokawa K: Symptoms of depression, prescription of benzodiazepines, and the risk of death in hemodialysis patients in Japan. Kidney Int 2006; 70: 1866–1872.
  11. Martin JL, Sainz-Pardo M, Furukawa TA, Martin-Sanchez E, Seoane T, Galan C: Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol 2007; 21: 774–782.
  12. Beland SG, Preville M, Dubois MF, Lorrain D, Voyer P, Bosse C, Grenier S, Moride Y: The association between length of benzodiazepine use and sleep quality in older population. Int J Geriatr Psychiatry 2011; 26: 908–915.
  13. Lader M, Tylee A, Donoghue J: Withdrawing benzodiazepines in primary care. CNS Drugs 2009; 23: 19–34.
  14. Voyer P, Preville M, Cohen D, Berbiche D, Beland SG: The prevalence of benzodiazepine dependence among community-dwelling older adult users in Quebec according to typical and atypical criteria. Can J Aging 2010; 29: 205–213.
  15. Verdoux H, Lagnaoui R, Begaud B: Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies. Psychol Med 2005; 35: 307–315.
  16. Wu CS, Wang SC, Chang IS, Lin KM: The association between dementia and long-term use of benzodiazepine in the elderly: nested case-control study using claims data. Am J Geriatr Psychiatry 2009; 17: 614–620.
  17. Barker MJ, Greenwood KM, Jackson M, Crowe SF: Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 2004; 18: 37–48.
  18. Buysse DJ, Reynolds CR, Monk TH, Berman SR, Kupfer DJ: The pittsburgh sleep quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193–213.
  19. Li J, Guo Q, Ye X, Lin J, Yi C, Mao H, Yang X, Yu X: Prevalence and risk factors of sleep disturbance in continuous ambulatory peritoneal dialysis patients in Guangzhou, southern China. Int Urol Nephrol 2012; 44: 929–936.
  20. Chen WC, Lim PS, Wu WC, Kuo HY, Tsai TW, Chien PI, Su YJ, Su YL, Hung SH, Woods HF: Sleep behavior disorders in a large cohort of Chinese (Taiwanese) patients maintained by long-term hemodialysis. Am J Kidney Dis 2006; 48: 277–284.
  21. Arab Z, Shariati AR, Asayesh H, Vakili MA, Bahrami-Taghanaki H, Azizi H: A sham-controlled trial of acupressure on the quality of sleep and life in haemodialysis patients. Acupunct Med 2016; 34: 2–6.
  22. Ware JJ, Kosinski M, Keller SD: A 12-Item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34: 220–233.
  23. Trbojevic-Stankovic J, Stojimirovic B, Bukumiric Z, Hadzibulic E, Andric B, Djordjevic V, Marjanovic Z, Birdjozlic F, Nesic D, Jovanovic D, et al: Depression and quality of sleep in maintenance hemodialysis patients. Srp Arh Celok Lek 2014; 142: 437–443.
    External Resources
  24. Scalo J, Desai P, Rascati K: Insomnia, hypnotic use, and health-related quality of life in a nationally representative sample. Qual Life Res 2015; 24: 1223–1233.
  25. Dashti-Khavidaki S, Chamani N, Khalili H, Hajhossein Talasaz A, Ahmadi F, Lessan-Pezeshki M, Ghaeli P, Dalili S, Alimadadi A: Comparing effects of clonazepam and zolpidem on sleep quality of patients on maintenance hemodialysis. Iran J Kidney Dis 2011; 5: 404–409.
    External Resources
  26. Berry RB, Patel PB: Effect of zolpidem on the efficacy of continuous positive airway pressure as treatment for obstructive sleep apnea. Sleep 2006; 29: 1052–1056.
  27. Grimaldi D, Provini F, Vetrugno R, Antelmi E, Donadio V, Liguori R, Pierangeli G, Cortelli P, Montagna P: Idiopathic central sleep apnoea syndrome treated with zolpidem. Neurol Sci 2008; 29: 355–357.
  28. Quadri S, Drake C, Hudgel DW: Improvement of idiopathic central sleep apnea with zolpidem. J Clin Sleep Med 2009; 5: 122–129.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: April 24, 2017
Accepted: November 02, 2017
Published online: December 12, 2017
Issue release date: Published online first (Issue-in-Progress)

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 4

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.